Engaging the Experts – A New Landscape: Biosimilars in Multiple Sclerosis
A New Landscape: Biosimilars in Autoimmune Indications
Accelerating Biosimilar Adoption: Conversation with the Experts
Checklists for workflow considerations relating to adalimumab biosimilars
The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems
Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
Health economics of disease-modifying therapy for multiple sclerosis in the United States
Era of biosimilars in rheumatology: reshaping the healthcare environment
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
A place for biosimilars in the changing multiple sclerosis treatment
